BIOGEN INC.

BIIB Healthcare & Pharma 2/10 Low Risk
2/10

BIOGEN INC. has $6.3B in total long-term debt with $6.6B in scheduled maturities. Approximately $0 (0% of maturities) is due within the next twelve months, and operating income covers interest expense 28.5x. Overall, BIIB carries low refinancing risk (score 2/10).

Maturity Schedule

Year 1 $0 Year 2 $0 Year 3 $0 Year 4 $0 Year 5 $1.5B Beyond 5 $5.1B
Period Amount Due % of Total
Year 1 (0-12 months) $0 0.0%
Year 2 (12-24 months) $0 0.0%
Year 3 (24-36 months) $0 0.0%
Year 4 (36-48 months) $0 0.0%
Year 5 (48-60 months) $1.5B 22.8%
Beyond 5 Years $5.1B 77.2%
Total Scheduled Maturities $6.6B 100.0%

Key Metrics

Total Long-Term Debt
$6.3B
Near-Term (12mo)
$0
Interest Coverage
28.5x
Debt/Equity
0.47
Cash Coverage
1.33x
Operating Income
$7.0B

Score Components

Component Value Weight
Near-Term Maturity Concentration 0.0% 30%
Interest Coverage Ratio 28.52x 25%
Debt-to-Equity Ratio 0.47 25%
Cash Coverage of Near-Term Debt 1.33x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-06. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Complete.